OxyContin, prescription opioid abuse and economic medicalization

Poitras, Geoffrey (2012): OxyContin, prescription opioid abuse and economic medicalization. Published in: Medicolegal and Bioethics , Vol. 2, (2012): pp. 31-43.

Abstract

This paper examines the relevance of OxyContin diversion and abuse to the economic medicalization of substance abuse and addiction. Given that medicalization is the general social process of nonmedical problems being transformed into medical problems, economic medicalization occurs where the motivation for the transformation is commercial profitability or, in a corporate context, achieving the objective of shareholder wealth maximization. After considering potential conflicts between medical ethics and business ethics, practical aspects of economic medicalization are detailed by considering the methods used to market OxyContin by Purdue Pharma. Illegal practices are identified and contrasted with legal practices that facilitated economic medicalization. Implications of medicalization research for designing public heath solutions to the epidemic of prescription opioid abuse are discussed.

• Item Type: MPRA Paper
• Language: English
• Keywords: medicalization, OxyContin, prescription drug abuse, medical ethics
• Subjects: I - Health, Education, and Welfare > I1 - Health; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health; I - Health, Education, and Welfare > I1 - Health > I19 - Other

References

1. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99:221–227.

2. Government Accounting Office. OxyContin abuse and diversion and efforts to address the problem: highlights of a government report. J Pain Palliat Care Pharmacother. 2004;18:109–113.

3. Government Accounting Office. OxyContin Abuse and Diversion and Efforts to Address the Problem. Washington, DC: GAO; 2003.

4. Poitras G., Meredith L. Ethical transparency and economic medicalization. J Bus Ethics. 2009;86:313–325.

5. Conrad P. The Medicalization of Society. Baltimore, MD: Johns Hopkins Press; 2007.

6. Conrad P. The shifting engines of medicalization. J Health Soc Behav. 2005;46:3–14.

7. Conrad P, Leiter V. Medicalization, markets and consumers. J Health Soc Behav. 2004;45 Suppl:158–176.

8. Poitras G. Medical ethics and economic medicalization. In: Clark P, editor. Contemporary Issues in Bioethics. Rijeka, Croatia: InTech; 2012.

9. Poitras G. Business ethics, medical ethics and economic medicalization. Int J Bus Govern Ethics. 2009;4:372–389.

10. Moloney M, Konrad T, Zimmer C. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011;101:1429–1433.

11. Poitras G. Shareholder wealth maximization, business ethics and social responsibility. J Bus Ethics. 1994;13:125–134.

12. Executive Office of the President of the United States. Epidemic: Responding to America’s Prescription Drug Abuse Crisis. 2011. Available from: http://www.whitehouse.gov/sites/default/files/ ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf. Accessed October 25, 2012.

13. Wootton B. Social Science and Social Pathology. New York, NY: Macmillan; 1959.

14. Szasz T. Psychiatry, ethics, and the criminal law. Columbia Law Rev. 1958;58:183–198.

15. Szasz T. Scientific method and social role in medicine and psychiatry. AMA Arch Intern Med. 1958;101:228–238.

16. Szasz T. The Myth of Mental Illness. New York, NY: Harper and Row; 1961.

17. Parsons T. The Social System. New York, NY: Free Press; 1951.

18. Davis J. How medicalization lost its way. Society. 2006;43:51–56.

19. Freidson E. Profession of Medicine. New York, NY: Dodd, Mead; 1970.

20. Zola I. Medicine as a institution of social control. Sociol Rev. 1972;20: 487–504.

21. Conrad P. Medicalization and social control. Annu Rev Sociol. 1992;18: 209–232.

22. Sismondi S. Pharmaceutical maneuvers. Soc Stud Sci. 2004;34: 149–159.

23. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Soc Stud Sci. 2004;34:219–245.

24. Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. New Engl J Med. 2006;355:2169–2171.

25. Jones G, Hagtvedt R. Marketing in heterozygous advantage. J Bus Ethics. 2008;77:85–87.

26. Centers for Disease Control and Prevention (CDC). CDC grand rounds: prescription drug overdoses – a US epidemic. MMWR Morb Mortal Wkly Rep. 2012;61:10–13.

27. American Medical Association. Code of Medical Ethics of the American Medical Association: Current Opinions with Annotations 2010–2011. Chicago, IL: American Medical Association; 2010.

28. McCullough L. John Gregory and the Invention of Professional Medical Ethics and the Profession of Medicine. Dordrecht, Netherlands: Kluwer; 1998.

29. Eaton M. Ethics and the Business of Bioscience. Stanford, CA: Stanford University Press; 2004.

30. Eaton M. Managing the risks associated with using biomedical ethics advice. J Bus Ethics. 2008;77:99–109.

31. Moynihan R, Cassels A. Selling Sickness: How the World’s Biggest Pharmaceutical Companies Are Turning Us All into Patients. Vancouver, BC: Greystone; 2005.

32. Brennan R, Eagle L, Rice D. Medicalization and marketing. J Macromarketing. 2010;30:8–22.

33. Caplovitz A. Turning Medicine into Snake Oil: How Pharmaceutical Marketers Put Patients at Risk. Trenton, NJ: New Jersey Public Interest Research Group Law and Policy Center; 2006.

34. Angell M. The Truth About Drug Companies: How They Deceive Us and What to Do about It. New York, NY: Random House; 2004.

35. Meier B. Pain Killer. Emmaus, PA: Rodale; 2003.

36. Porter J, Jick H. Addiction rare in patients treated with narcotics. New Engl J Med. 1980;302:123.

37. Perry S, Heidrich G. Management of pain during debridement: a survey of US burn units. Pain. 1982;13:267–280.

38. Donohue J, Cevasco M, Rosenthal M. A decade of direct-to-consumer advertising of prescription drugs. New Engl J Med. 2007;357: 673–681.

39. Greene J. Attention to ‘details’: etiquette and the pharmaceutical salesmen in postwar USA. Soc Stud Sci. 2004;34:271–292.

40. Chew L, O’Young T, Hazlet T, Bradley K, Maynard C, Lessler D. A physician survey of the effect of drug sample availability on physicians’ behavior. J Gen Intern Med. 2000;15:478–483.

41. Campbell E. Doctors and drug companies: scrutinizing influential relationships. New Engl J Med. 2007;357:1796–1797.

42. Warner M, Chen L, Makuc D, Anderson R, Miniño A. Drug poisoning deaths in the United States, 1980–2008. NCHS Data Brief. 2011:81.

43. Lofwall M, Moody D, Fang W, Nuzzo P, Walsh S. Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers. J Clin Pharmacol. 2012;52: 600–606.

44. Carise D, Dugosh K, McLellan A, Camilleri A, Woody G, Lynch K. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–1756.

45. Jones J, Vosburg S, Manubay M, Comer S. Oxycodone abuse in New York City: characteristics of intravenous and intranasal users. Am J Addict. 2011;20:190–195.

46. Jonas A, Young A, Oser C, Leukefeld C, Havens J. OxyContin as currency: OxyContin use and increased social capital among rural Appalachian drug users. Soc Sci Med. 2012;74:1602–1609.

47. Cicero T, Inciardi J, Munoz A. Trends in the abuse of OxyContin and other analgesics in the United States: 2002–2004. J Pain. 2005;6: 662–672.

48. Centers for Disease Control and Prevention (CDC). Overdose deaths involving prescription opioids among Medicaid enrollees – Washington, 2004–2007. MMWR Morb Mortal Wkly Rep. 2009;58:1171–1175.

49. Levy M. An exploratory study of OxyContin use among individuals with substance use disorders. J Psychoactive Drugs. 2007;39:271–276.

50. Sees K, Di Marino M, Ruediger N, Sweeney C, Shiffman S. Non-medical use of OxyContin tablets in the United States. J Pain Palliat Care Pharmacother. 2005;19:13–23.

51. Grau L, Dasgupta N, Harvey A, et al. Illicit use of opioids: is OxyContin a ‘gateway drug’? Am J Addict. 2007;16:166–173.

52. Hays L. A profile of OxyContin addiction. J Addict Dis. 2004;23: 1–9.

53. Rawson R, Maxwell J, Rutkowski B. OxyContin abuse: who are the users? Am J Psychiatry. 2007;164:1634–1636.

54. Swann J. Drug abuse control under FDA, 1938–1968. Public Health Rep. 1997;112:83–86.

55. Cicero T, Ellis M, Surratt H. Effect of abuse-deterrent formulation of OxyContin. New Engl J Med. 2012;367:187–189.